A Partnership Built to Succeed
By joining forces, Public Health Vaccines, LLC and Crozet BioPharma, LLC are applying their collective vaccine expertise to build a safe and effective novel vaccine against Nipah virus disease, with funding from CEPI.
Our goal is to develop a single-dose Nipah vaccine that is well-tolerated and effective by employing novel technologies and product development strategies to address this major unmet public health need. In the World Health Organization R&D Blueprint, Nipah has been named a priority diseases for fast track vaccine development.
Nipah by the Numbers
Frequently Asked Questions
Check out our FAQ page for answers to the most frequently asked questions about the Nipah virus and our vaccine project.
A Novel Vaccine Development Method
The Nipah vaccine being developed by PHV and Crozet uses recombinant DNA technology. Like many of the most successful vaccines used to protect against infectious diseases (e.g. measles, mumps, German measles, chickenpox, smallpox, oral polio, rotavirus, yellow fever), the recombinant vaccine against Nipah is a live, replication competent vaccine, engineered to balance safety and effectiveness.
